Compare AbCellera Biologics Inc (ABCL) vs Fabrinet (FN) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

FN trades at $500.75, up 0.23% with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with 75% buy ratings and a $733 price target, representing 46% upside potential from current levels. Recent news highlights FN's strategic position in AI optical supply chain with capacity expansion supporting multi-year growth visibility.

The outlook remains positive driven by AI infrastructure demand and strong execution, though premium valuation metrics (P/E 43.02) and technical bearish signals warrant caution. Key risks include datacom supply constraints and FX volatility, but robust revenue growth projections ($4.2B for 2026) and expanding margins support the bullish analyst stance.